RA Capital Management
VC Fund
Boston, United States
RA Capital Management is an investment advisor based in Boston specializing in the life-sciences and drug development sectors. The company's team has been investing since 2002 and is comprised of professionals with training in biology, chemistry, and medicine and also has industry and business development experience at the executive and boardlevels. The company invests in companies with promising technologies and products.
- Total investments:
- 578
- Last investment:
- Lead investor:
- 35%
- Fund size:
- $120M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries RA Capital Management invests in
Stages RA Capital Management invests in
Countries RA Capital Management invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 21 contacts → | |||
Round size
- Series A
- $20M–$128M
- Series B
- $27M–$151M
- Post-IPO Equity
- $35M–$275M
Investment Focus
Industry
- Biotechnology 325 (56%)
- Health Care 205 (35%)
- Therapeutics 148 (26%)
- Medical 122 (21%)
- Pharmaceutical 109 (19%)
Stage
- Series B 133 (23%)
- Post-IPO Equity 100 (17%)
- Series A 81 (14%)
- Series C 79 (14%)
- Series D 29 (5%)
Country
- United States 311 (54%)
- United Kingdom 12 (2%)
- China 9 (2%)
- Denmark 8 (1%)
- Canada 7 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Cristina Ghenoiu
Principal
|
Principal | Total investments: 2 | Find email | |
Ajay Yekkirala
VP, Head of Biology
|
VP, Head of Biology | Total investments: 0 | Find email | |
Andrew Levin
Managing Director
|
Managing Director | Total investments: 24 | Find email | |
Barbara Herbst
Deputy Chief Compliance Officer
|
Deputy Chief Compliance Officer | Total investments: 0 | Find email | |
Dan Marks
Venture Senior Associate
|
Venture Senior Associate | Total investments: 1 | Find email | |
| See all 21 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Lisata Therapeutics is a clinical-stage pharmaceutical company developing therapies based on clear differentiation and rigorous data applied in areas of high unmet medical need. They focus on the discovery, development, and commercialization of therapies for the treatment of solid tumors and other major diseases. | $225M / Post-IPO Equity / Sep 17, 2026 | ||
| Circle Pharma is an early-stage biotechnology company applying proprietary computational design algorithms and innovative chemistry to develop cell-permeable macrocycle peptide therapeutics against important clinical targets. It does this through an iterative, rational design process that deploys large virtual libraries of conformationally diversemacrocycle scaffolds selected for inherent permeability. The company was founded by Matt Jacobson and Scott Lokey in 2012 and is headed by David J. Earp. | $92.5M / Series E / Sep 16, 2026 | ||
| Planted Solar focuses on driving the transition of clean energy. | $31.8M / Venture - Series Unknown / Sep 15, 2026 | ||
| Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. Tyra is using its proprietary SNÅP platform, which is optimized to enable rapid and precise refinement of structural design through iterative molecular SNÅPshots, in orderto generate next-generation product candidates that are specifically designed to address acquired drug resistance and provide alternative treatment options. Tyra is initially focused on developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor, or FGFR, family, which are altered in approximately 7% of all cancers. Tyra’s lead product candidate, TYRA-300, is designed to selectively inhibit FGFR3, with an initial focus on patients with bladder cancer. | $400M / Post-IPO Equity / Sep 14, 2026 | ||
| Solstice Oncology is a clinical stage immuno-oncology company developing a therapeutic that meets cancer at its most vulnerable moment, before surgery, to drive deep pathological response and return patients to lasting health. The company's lead program is targeting colon cancer. | $225M / Series A / Sep 09, 2026 | ||
CaMaRa
|
CaMaRa is a biotechnology company developing new medicines for cardiometabolic conditions, including obesity, diabetes and kidney disease. | Seed / Sep 09, 2026 | |
| Tectora Therapeutics develops oral medicines designed to treat immune-mediated diseases, specifically focusing on immunology and inflammation. The company co-develops its pipeline by utilizing advanced computational drug discovery platforms and preclinical capabilities. Its core value proposition centers on translating clinically validated biologyinto oral small-molecule therapies to address significant unmet patient needs. | $55M / Series A / Sep 09, 2026 | ||
| Korsana Biosciences develops THETA-enabled antibody therapies for neurodegenerative diseases. The company focuses on shuttled monoclonal antibodies that cross the blood-brain barrier to reach central nervous system targets. Its lead program, KRSA-028, is an investigational anti-amyloid beta antibody for Alzheimer’s disease that uses a transferrinreceptor-based shuttle and Fc engineering to improve brain delivery and dosing. Korsana is also advancing additional THETA-based programs for undisclosed neurodegenerative indications. | $380M / Post-IPO Equity / Sep 08, 2026 | ||
| Superluminal Medicines is a generative biological and chemical company accelerating new possibilities in drug discovery and development. Its platform creates candidate-ready compounds with speed using a comprehensive combination of deep biology and chemistry expertise, machine learning, and proprietary big data infrastructure. | $65.5M / Series B / Sep 03, 2026 | ||
| Typewriter Therapeutics, Inc. develops mRNA-based gene therapies using a gene writing, or gene writing, platform for precise insertion of therapeutic genes into the genome. The company builds on transposon-based technologies originating from research by Professor Emeritus Haruhiko Fujiwara at the University of Tokyo. Its programs focus on all‑RNA,nonviral gene writing systems that repurpose natural genetic elements to address severe genetic disorders with limited treatment options. Typewriter Therapeutics conducts research and development across its U.S. and Japan operations and collaborates with investors and partners to advance genetic medicine candidates toward the clinic. | $56.3M / Series A / Sep 02, 2026 | ||
| See all 578 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does RA Capital Management invest in?
RA Capital Management invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Post-IPO Equity stage. Most of the 578 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is RA Capital Management's check size?
RA Capital Management typically joins rounds of $20M–$128M at Series A, $27M–$151M at Series B and $35M–$275M at Post-IPO Equity. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds RA Capital Management participates in.
How do I contact RA Capital Management?
Public channels for RA Capital Management include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at RA Capital Management?
The team at RA Capital Management includes Cristina Ghenoiu (Principal), Ajay Yekkirala (VP, Head of Biology) and Andrew Levin (Managing Director), among 21 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
